Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Laboratory Of Coordination Chemistry Of The French National Centre For Scientific Research holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This matter is assigned to 1 distinct art unit, indicating that the current intellectual property efforts are focused on a specific technical division within the biotechnology sector.
The prosecution involves 1 distinct examiner, BAEK, JONGHWAN NMN. As the busiest examiner for the portfolio, BAEK, JONGHWAN NMN is currently managing 1 busiest examiner pending office action. This 1 pending action represents the entirety of the active workload at the patent office, which suggests a focused prosecution strategy.
Practitioners can focus their efforts on the 1 pending office action and the specific examination style of BAEK, JONGHWAN NMN. Because the portfolio is concentrated in 1 distinct art unit with 1 distinct examiner, the firm can develop a targeted approach. This allows for a deep focus on the technical requirements of the Biotechnology & Pharmaceuticals area as they apply to the 1 pending office action currently under review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18305553 | MULTIFUNCTIONAL CONTRAST AGENTS, COMPOSITIONS, AND METHODS | BAEK, JONGHWAN NMN | 53d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18305553 | MULTIFUNCTIONAL CONTRAST AGENTS, COMPOSITIONS, AND METHODS | BAEK, JONGHWAN NMN | 1618 | §102§112 | Non-Final OA | 53d | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial